Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Recruiting

Phase 1

Phase 2

ONC-PluReceptor, Epcoritamab, TafasitamabTrial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07283679

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma

Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONC-PluReceptor NK cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-03. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-05-01.